Crohn’s Disease Therapy STELARA Showed Efficacy in Phase III Trial

Crohn’s Disease Therapy STELARA Showed Efficacy in Phase III Trial
Results on a pivotal Janssen Research & Development, LLC-commissioned Phase III clinical trial, called UNITI-2, on STELARA® (ustekinumab) for moderate to severe Crohn’s disease were recently reported and provided the first evidence of the drug’s ability to induce clinical response and remission in patients who were unresponsive to traditional treatments. STELARA, a monoclonal antibody formulated to target interleukin

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *